<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>CORTENEMA- hydrocortisoneÂ enemaÂ </strong><br>ANIP Acquisition Company<br></p></div>
<h1>CORTENEMAÂ®<br>hydrocortisone retention enema<br>100 mg / 60 mLÂ <br>DISPOSABLE UNIT FOR RECTAL USE ONLY</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_id_87e2d6d4-5fb2-49d5-8c07-b10ee601c74d"></a><a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Hydrocortisone is a white to practically white, odorless, crystalline powder, very slightly soluble in water. It has the chemical name Pregn-4-ene-3,20-dione,11,17,21-trihydroxy,(11Î²)-and the following structural formula: </p>
<div class="Figure"><img alt="Chemical Structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-01.jpg"></div>
<p>CORTENEMAÂ® is a convenient disposable single-dose hydrocortisone enema designed for ease of self-administration. </p>
<p>Each disposable unit (60 mL) contains: Hydrocortisone, 100 mg in an aqueous solution containing carbomer 934P, polysorbate 80, purified water, sodium hydroxide and methylparaben, 0.18% as a preservative. </p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_id_5b4b7df9-1cef-4be8-b5ed-58937d1de143"></a><a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Hydrocortisone is a naturally occurring glucocorticoid (adrenal corticosteroid), similar to its acetate and sodium hemisuccinate derivatives, is partially absorbed following rectal administration. Absorption studies in <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> patients have shown up to 50% absorption of hydrocortisone administered as CORTENEMAÂ® and up to 30% of hydrocortisone acetate administered in an identical vehicle. </p>
<p>CORTENEMAÂ® provides the potent anti-inflammatory effect of hydrocortisone. Because this drug is absorbed from the colon, it acts both topically and systemically. Although rectal hydrocortisone, used as recommended for CORTENEMAÂ®, has a low incidence of reported adverse reactions, prolonged use presumably may cause systemic reactions associated with oral dosage forms. </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_id_f8c72642-4d09-48e7-8150-b703a0d867b3"></a><a name="section-3"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">CORTENEMAÂ® is indicated as adjunctive therapy in the treatment of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, especially distal forms, including <span class="product-label-link" type="condition" conceptid="75580" conceptname="Chronic ulcerative proctitis">ulcerative proctitis</span>, ulcerative proctosigmoiditis, and left-sided <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. It has proved useful also in some cases involving the transverse and ascending colons. </p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_id_67a3b820-cbd1-4013-9830-482227f33818"></a><a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First">Systemic <span class="product-label-link" type="condition" conceptid="432248" conceptname="Opportunistic mycosis">fungal infections</span>; and ileocolostomy during the immediate or early post-operative period. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_id_1398f259-139f-4d42-8e48-2594a6597534"></a><a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>, it is hazardous to delay needed surgery while awaiting response to medical treatment. </p>
<p>Damage to the rectal wall can result from careless or improper insertion of an enema tip. </p>
<p>In patients on corticosteroid therapy subjected to unusual stress, increased dosage of rapidly acting corticosteroids before, during, and after the stressful situation is indicated. </p>
<p>Corticosteroids may mask some signs of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, and new <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> may appear during their use. There may be decreased resistance and inability to localize <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> when corticosteroids are used. </p>
<p>Prolonged use of corticosteroids may produce <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">posterior subcapsular cataracts</span>, <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span> with possible damage to the optic nerves, and may enhance the establishment of secondary ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> due to fungi or viruses. </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_f11dd50f-b68b-4674-b5c1-8a067545e0ac"></a><a name="section-5.1"></a><p></p>
<h2>Usage In Pregnancy</h2>
<p class="First">Since adequate human reproduction studies have not been done with corticosteroids, the use of these drugs in pregnancy, nursing mothers or women of child-bearing potential requires that the possible benefits of the drug be weighed against the potential hazards to the mother and embryo or fetus. Neonates born of mothers who have received substantial doses of corticosteroid during pregnancy should be carefully observed for signs of <span class="product-label-link" type="condition" conceptid="193984" conceptname="Adrenal hypofunction">hypoadrenalism</span>. </p>
<p>Average and large doses of hydrocortisone or cortisone can cause elevation of blood pressure, salt and <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">water retention</span>, and increased excretion of potassium. These effects are less likely to occur with the synthetic derivatives except when used in large doses. Dietary salt restriction and potassium supplementation may be necessary. All corticosteroids increase calcium excretion. </p>
<p><span class="Bold">While on corticosteroid therapy patients should not be vaccinated against <span class="product-label-link" type="condition" conceptid="134573" conceptname="Smallpox">smallpox</span>. Other immunization procedures should not be undertaken in patients who are on corticosteroids, especially on high dose, because of possible hazards of neurological complications and a lack of antibody response. </span></p>
<p>Persons who are on drugs which suppress the immune system are more susceptible to <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> than healthy individuals. Chicken pox and <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, for example, can have a more serious or even fatal course in non-immune pediatric patients or adults on corticosteroids. In such pediatric patients or adults who have not had these diseases, particular care should be taken to avoid exposure. How the dose, route and duration of corticosteroid administration affects the risk of developing a disseminated <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is not known. The contribution of the underlying disease and/or prior corticosteroid treatment to the risk is also not known. If exposed to chicken pox, prophylaxis with <span class="product-label-link" type="condition" conceptid="443943" conceptname="Herpes zoster">varicella zoster</span> immune globulin (VZIG) may be indicated. If exposed to <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>, prophylaxis with pooled intramuscular immunoglobulin (IG) may be indicated. (See the respective package inserts for complete VZIG and IG prescribing information.) If chicken pox develops, treatment with antiviral agents may be considered. </p>
<p>If corticosteroids are indicated in patients with latent <span class="product-label-link" type="condition" conceptid="434557" conceptname="Tuberculosis">tuberculosis</span> or tuberculin reactivity, close observation is necessary as reactivation of the disease may occur. During prolonged corticosteroid therapy, these patients should receive chemoprophylaxis. </p>
</div>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_id_3ef7ea50-e6bc-42c4-ae86-9934ef61b126"></a><a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_id_c8876adc-a58f-4dff-9d79-5b2a7e48e38a"></a><a name="section-6.1"></a><p></p>
<h2>General</h2>
<p class="First">CORTENEMAÂ® hydrocortisone retention enema should be used with caution where there is a probability of impending perforation, <span class="product-label-link" type="condition" conceptid="444202" conceptname="Abscess">abscess</span> or other pyogenic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>; fresh intestinal anastomoses; obstruction; or extensive <span class="product-label-link" type="condition" conceptid="4043006" conceptname="Fistula">fistulas</span> and sinus tracts. Use with caution in presence of active or latent <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">peptic ulcer</span>; <span class="product-label-link" type="condition" conceptid="4109737" conceptname="Diverticulitis">diverticulitis</span>; <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal insufficiency</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>; and <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>. </p>
<p>Steroid therapy might impair prognosis in surgery by increasing the hazard of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>. If <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span> is suspected, appropriate antibiotic therapy must be administered, usually in larger than ordinary doses. </p>
<p>Drug-induced <span class="product-label-link" type="condition" conceptid="4042063" conceptname="Hypocortisolism secondary to another disorder">secondary adrenocortical insufficiency</span> may occur with prolonged CORTENEMAÂ® therapy. This is minimized by gradual reduction of dosage. This type of relative insufficiency may persist for months after discontinuation of therapy; therefore, in any situation of stress occurring during that period, hormone therapy should be reinstituted. Since mineralocorticoid secretion may be impaired, salt and/or a mineralocorticoid should be administered concurrently. </p>
<p>There is an enhanced effect of corticosteroids on patients with <span class="product-label-link" type="condition" conceptid="140673" conceptname="Hypothyroidism">hypothyroidism</span> and in those with cirrhosis. </p>
<p>Corticosteroid should be used cautiously in patients with ocular herpes simplex because of possible <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. </p>
<p>The lowest possible dose of corticosteroid should be used to control the conditions under treatment, and when reduction in dosage is possible, the reduction should be gradual. </p>
<p>Psychic derangement may appear when corticosteroids are used, ranging from <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">mood swings</span>, <span class="product-label-link" type="condition" conceptid="444092" conceptname="Personality change">personality changes</span>, and severe <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>, to frank <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> manifestations. Also, existing <span class="product-label-link" type="condition" conceptid="4078201" conceptname="Mood swings">emotional instability</span> or <span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">psychotic</span> tendencies may be aggravated by corticosteroids. </p>
<p>Aspirin should be used cautiously in conjunction with corticosteroids in <span class="product-label-link" type="condition" conceptid="4253058" conceptname="Factor II deficiency">hypoprothrombinemia</span>. </p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_id_74317789-181c-497d-880e-a5fd175ae7a7"></a><a name="section-6.2"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">Safety and effectiveness in pediatric patients have not been established. </p>
<p>Growth and development of pediatric patients on prolonged corticosteroid therapy should be carefully observed. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_id_0305f19c-534a-4b5c-bee9-6b88344e3686"></a><a name="section-6.3"></a><p></p>
<h2>Information for Patients</h2>
<p class="First">Persons who are on immunosuppressant doses of corticosteroids should be warned to avoid exposure to chicken pox or <span class="product-label-link" type="condition" conceptid="4030555" conceptname="Measles">measles</span>. Patients should also be advised that if they are exposed, medical advice should be sought without delay. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_id_4122bcff-b21b-4847-aad5-2ca3a9e9c042"></a><a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Local <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> or burning, and <span class="product-label-link" type="condition" conceptid="197925" conceptname="Hemorrhage of rectum and anus">rectal bleeding</span> attributed to CORTENEMAÂ® have been reported rarely. Apparent exacerbations or sensitivity reactions also occur rarely. The following adverse reactions should be kept in mind whenever corticosteroids are given by rectal administration. <br>Â </p>
<p><span class="Bold">Fluid and <span class="product-label-link" type="condition" conceptid="4022093" conceptname="Electrolyte imbalance">Electrolyte Disturbances</span>:</span> <span class="product-label-link" type="condition" conceptid="4190305" conceptname="Hypernatremia">Sodium retention</span>; <span class="product-label-link" type="condition" conceptid="4125002" conceptname="Idiopathic fluid retention">fluid retention</span>; <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span> in susceptible patients; potassium loss; <span class="product-label-link" type="condition" conceptid="4332017" conceptname="Hypokalemic alkalosis">hypokalemic alkalosis</span>; <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>. <span class="Bold">Musculoskeletal:</span> <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">Muscle weakness</span>; <span class="product-label-link" type="condition" conceptid="4097390" conceptname="Steroid-induced myopathy">steroid myopathy</span>; loss of <span class="product-label-link" type="condition" conceptid="4152202" conceptname="Form of muscle">muscle mass</span>; <span class="product-label-link" type="condition" conceptid="80502" conceptname="Osteoporosis">osteoporosis</span>; vertebral <span class="product-label-link" type="condition" conceptid="4071579" conceptname="Compression fracture">compression fractures</span>; asceptic <span class="product-label-link" type="condition" conceptid="4280654" conceptname="Necrosis">necrosis</span> of femoral and humeral heads; pathologic <span class="product-label-link" type="condition" conceptid="75053" conceptname="Fracture of bone">fracture</span> of long bones. <span class="Bold">Gastrointestinal:</span> <span class="product-label-link" type="condition" conceptid="4027663" conceptname="Peptic ulcer">Peptic ulcer</span> with possible perforation and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span>; <span class="product-label-link" type="condition" conceptid="4192640" conceptname="Pancreatitis">pancreatitis</span>; abdominal <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">distention</span>; ulcerative <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. <span class="Bold">Dermatologic:</span> Impaired <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wound</span> healing; thin fragile skin; <span class="product-label-link" type="condition" conceptid="4155911" conceptname="Petechiae">petechiae</span> and <span class="product-label-link" type="condition" conceptid="4118793" conceptname="Ecchymosis">ecchymoses</span>; facial <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span>; increased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>; may suppress reactions to skin tests. <span class="Bold">Neurological:</span> <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">Convulsions</span>; <span class="product-label-link" type="condition" conceptid="4154803" conceptname="Raised intracranial pressure">increased intracranial pressure</span> with <span class="product-label-link" type="condition" conceptid="4308632" conceptname="Optic disc edema">papilledema</span> (pseudo-tumor cerebri) usually after treatment; <span class="product-label-link" type="condition" conceptid="439383" conceptname="Vertigo">vertigo</span>; <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>. <span class="Bold">Endocrine:</span> Menstrual irregularities; development of <span class="product-label-link" type="condition" conceptid="4195232" conceptname="Cushingoid facies">Cushingoid</span> state; suppression of growth in pediatric patients; secondary adrenocortical and pituitary unresponsiveness, particularly in times of stress, as in <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, surgery or illness, decreased carbohydrate tolerance; manifestations of <span class="product-label-link" type="condition" conceptid="4311629" conceptname="Impaired glucose tolerance">latent diabetes</span> requirements for insulin or oral hypoglycemic agents in diabetics. <span class="Bold">Ophthalmic:</span> <span class="product-label-link" type="condition" conceptid="375256" conceptname="Anterior subcapsular polar senile cataract">Posterior subcapsular cataracts</span>; <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="436700" conceptname="Exophthalmos">exophthalmos</span>. <span class="Bold">Metabolic:</span> Negative nitrogen balance due to protein catabolism. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_id_02b9e721-dee8-4cdc-9a1d-da7034367ae1"></a><a name="section-8"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">The use of CORTENEMAÂ® hydrocortisone retention enema is predicated upon the concomitant use of modern supportive measures such as rational dietary control, sedatives, antidiarrheal agents, antibacterial therapy, blood replacement if necessary, etc. </p>
<p>The usual course of therapy is one CORTENEMAÂ® nightly for 21 days, or until the patient comes into remission both clinically and proctologically. Clinical symptoms usually subside promptly within 3 to 5 days. Improvement in the appearance of the mucosa, as seen by sigmoidoscopic examination, may lag somewhat behind clinical improvement. Difficult cases may require as long as 2 or 3 months of CORTENEMAÂ® treatment. Where the course of therapy extends beyond 21 days, CORTENEMAÂ® should be discontinued gradually by reducing administration to every other night for 2 or 3 weeks. </p>
<p>If clinical or proctologic improvement fails to occur within 2 or 3 weeks after starting CORTENEMAÂ®, discontinue its use. </p>
<p>Symptomatic improvement, evidenced by decreased <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> and <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span>; <span class="product-label-link" type="condition" conceptid="4134784" conceptname="Weight increased">weight gain</span>; improved appetite; lessened <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>; and decrease in <span class="product-label-link" type="condition" conceptid="438398" conceptname="Leukocytosis">leukocytosis</span>, may be misleading and should not be used as the sole criterion in judging efficacy. Sigmoidoscopic examination and X-ray visualization are essential for adequate monitoring of <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span>. Biopsy is useful for differential diagnosis. </p>
<p>Patient instructions for administering CORTENEMAÂ® are enclosed in each box. It is recommended that the patient lie on their left side during administration and for 30 minutes thereafter, so that the fluid will distribute throughout the left colon. Every effort should be made to retain the enema for at least an hour and preferably, all night. This may be facilitated by prior sedation and/or antidiarrheal medication, especially early in therapy when the urge to evacuate is great. </p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_id_f335b605-8c96-454c-bfbe-55ba7b3ba74e"></a><a name="section-9"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">CORTENEMAÂ®, hydrocortisone 100 mg retention enema, is supplied as disposable single-dose bottles with lubricated rectal applicator tips, in boxes of seven x 60 mL (NDC 62559-111-07) and boxes of one x 60 mL (NDC 62559-111-11). </p>
<p>Store at controlled room temperature 20Â° - 25Â°C (68Â° - 77Â°F). [See USP Controlled Room Temperature.] </p>
<p><span class="Bold">Rx ONLY </span></p>
<p><img alt="Company Logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-02.jpg"></p>
<p>Manufactured by</p>
<p>ANI Pharmaceuticals, Inc.</p>
<p>Baudette, MN 56623</p>
<p>9156 Rev 11/11</p>
</div>
<div class="Section" data-sectionCode="59845-8">
<a name="i4i_instructions_for_use_id_895a484f-93d5-46da-91ba-b35367567e5c"></a><a name="section-10"></a><p></p>
<h1>Patient Instructions</h1>
<p class="First"><span class="Bold">How to use the retention enema: </span></p>
<p>Best results are achieved if the bowel is emptied immediately before the enema is given. </p>
<p><span class="Bold">1. Preparing the Medication for Administration </span></p>
<p><span class="Bold">a</span> Shake the bottle well to make sure that the suspension is homogeneous. </p>
<p><span class="Bold">b</span> Remove the protective sheath from the applicator tip. Hold the bottle at the neck so as not to cause any of the medication to be discharged. </p>
<div class="Figure"><img alt="Step 1b Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-03.jpg"></div>
<p><span class="Bold">2. Assuming the Correct Body Position </span></p>
<p><span class="Bold">a </span>Best results are obtained by lying on left side with the left leg extended and the right leg flexed forward for balance. </p>
<div class="Figure"><img alt="Step 2a Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-04.jpg"></div>
<p><span class="Bold">b</span> An alternative to lying on the left side is the â€œknee-chestâ€? position as shown here. </p>
<div class="Figure"><img alt="Step 2b Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-05.jpg"></div>
<p><span class="Bold">3. Administering the Retention Enema </span></p>
<p><span class="Bold">a</span> Gently insert the lubricated applicator tip into the rectum, pointed slightly toward the navel (umbilicus). </p>
<p><span class="Bold">b</span> Grasp the bottle firmly, then tilt slightly so that the nozzle is aimed toward the back, and squeeze slowly to instill the medication. Steady hand pressure will discharge most of the solution. After administering, withdraw and discard the used unit. </p>
<div class="Figure"><img alt="Step 3b Image" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-06.jpg"></div>
<p><span class="Bold">c</span> Remain in position for at least 30 minutes to allow thorough distribution of the medication internally. Retain the enema all night, if possible.</p>
<p><img alt="company logo" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-07.jpg"></p>
<p>Manufactured by</p>
<p>ANI Pharmaceuticals, Inc.</p>
<p>Baudette, MN 56623</p>
<p>9156 Rev 11/11</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="i4i_Principal_display_panel_id_b79791e1-6ecd-4904-8f07-c49120ea1cfa"></a><a name="section-11"></a><p></p>
<h1>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</h1>
<div class="Figure">
<img alt="Principal Display Panel - Carton Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=a307448a-ccc4-41a8-977a-11f28f0bded9&amp;name=a307448a-ccc4-41a8-977a-11f28f0bded9-08.jpg"><p class="MultiMediaCaption">Carton Label</p>
</div>
<p class="First">NDC 62559-111-11</p>
<p>UNIT DOSE 1 x 60 mL</p>
<p>THIS END UP</p>
<p><span class="Bold">Cortenema</span>Â®</p>
<p>hydrocortisone retention enema</p>
<p><span class="Bold">100 mg/60 mL</span></p>
<p>USUAL DOSE: One 60 mL enema daily before retiring.</p>
<p>See enclosed directions for use.  See package insert for additional prescribing information.</p>
<p>Each disposable unit (60 mL) contains: Hydrocortisone, 100 mg in an</p>
<p>aqueous solution containing carbomer 934P, polysorbate 80, purified</p>
<p>water, sodium hydroxide and methylparaben, 0.18% as a preservative.</p>
<p><span class="Bold">FOR RECTAL USE ONLY.</span></p>
<p><span class="Bold">SHAKE WELL BEFORE USE.</span></p>
<p>Store at controlled room temperature, 20Â°-25Â°C (68Â°-77Â°F)</p>
<p>(See USP Controlled Temperature.)</p>
<p><span class="Bold">Rx only</span></p>
<p>ANI Pharmaceuticals, Inc.</p>
<p>Baudette, MN 56623</p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>CORTENEMAÂ 		
					</strong><br><span class="contentTableReg">hydrocortisone enema</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:62559-111</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">RECTAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROCORTISONE</strong> (HYDROCORTISONE) </td>
<td class="formItem">HYDROCORTISONE</td>
<td class="formItem">100Â mg Â inÂ 60Â mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CARBOMER HOMOPOLYMER TYPE B (ALLYL SUCROSE CROSSLINKED)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>POLYSORBATE 80</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:62559-111-11</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:62559-111-07</td>
<td class="formItem">7  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">60 mL in 1 BOTTLE, UNIT-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA016199</td>
<td class="formItem">08/10/2012</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>ANIP Acquisition Company
							(145588013)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2012<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a307448a-ccc4-41a8-977a-11f28f0bded9</div>
<div>Set id: a307448a-ccc4-41a8-977a-11f28f0bded9</div>
<div>Version: 1</div>
<div>Effective Time: 20120813</div>
</div>
</div>Â <div class="DistributorName">ANIP Acquisition Company</div></p>
</body></html>
